Jaundice — Clinical Documentation Guide (2026)

🔍 Definition

Jaundice (icterus) is the yellow discoloration of the skin, sclerae, and mucous membranes caused by elevated serum bilirubin levels, generally becoming clinically visible when total serum bilirubin exceeds approximately 2–3 mg/dL in adults and 5 mg/dL in neonates. Bilirubin is a byproduct of heme catabolism: red blood cells are broken down, heme is oxidized to biliverdin and then reduced to unconjugated (indirect) bilirubin, which is bound to albumin and transported to the liver. There, hepatocytes conjugate bilirubin with glucuronic acid (via UGT1A1) to form water-soluble conjugated (direct) bilirubin, which is excreted into bile and ultimately eliminated in stool as urobilinogen (StatPearls — Jaundice).

Three broad pathophysiologic categories drive jaundice: (1) pre-hepatic (hemolytic) — excess bilirubin production overwhelms hepatic conjugation; (2) hepatic (hepatocellular) — impaired uptake, conjugation, or excretion within hepatocytes; and (3) post-hepatic (obstructive/cholestatic) — bile flow is physically or functionally obstructed, preventing excretion. Neonatal jaundice is a distinct, highly prevalent entity: physiologic hyperbilirubinemia affects up to 60% of term neonates in the first week of life due to fetal hemoglobin breakdown, immature hepatic conjugation capacity, and enterohepatic recirculation (AAP Clinical Practice Guideline on Hyperbilirubinemia).

For coding and CDI purposes, precise documentation of jaundice type, etiology, bilirubin fractionation (total vs. direct/conjugated), severity, and treatment threshold is required to support appropriate code selection across neonatal, pediatric, adult, and obstetric populations.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Clinical presentation varies by age group and etiology. Key findings that support documentation specificity include:

• Icteric sclerae — often the earliest visible sign in adults (detectable at bilirubin ~2 mg/dL); in neonates, assessed by blanching the skin under a light source
• Yellow skin discoloration — cephalocaudal progression in neonates (Kramer zones); generalized in adults
• Dark urine (bilirubinuria) — tea-colored or cola-colored urine indicates conjugated (direct) hyperbilirubinemia (obstructive or hepatocellular); absent in pure unconjugated hyperbilirubinemia
• Pale/clay-colored stools (acholia) — hallmark of biliary obstruction; indicates absence of bilirubin in stool
• Pruritus — prominent in cholestatic conditions (bile acid accumulation); characteristic of intrahepatic cholestasis of pregnancy
• Hepatomegaly / splenomegaly — hepatosplenomegaly suggests hemolytic anemia or portal hypertension
• Neonatal-specific: poor feeding, lethargy, high-pitched cry, hypotonia — early warning signs of acute bilirubin encephalopathy; opisthotonus and seizures indicate advanced kernicterus
• Fever, right upper quadrant pain, and jaundice (Charcot’s triad) — classic for choledocholithiasis with cholangitis
• Ascites, spider angiomata, palmar erythema, caput medusae — signs of portal hypertension / cirrhotic hepatocellular cause

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

The following clinical indicators, when documented in the medical record, support specific and complete ICD-10-CM code assignment. CDI professionals should query when these indicators are present but the specific etiology or type has not been documented by the treating clinician.

🦴 Anatomy & Pathophysiology

Bilirubin Metabolism Pathway: Approximately 80% of bilirubin derives from senescent RBC hemoglobin catabolism in reticuloendothelial cells (spleen, liver, bone marrow). Heme oxygenase converts heme to biliverdin; biliverdin reductase converts biliverdin to unconjugated bilirubin. Unconjugated bilirubin is lipid-soluble, albumin-bound, and crosses the blood-brain barrier — making it neurotoxic at high levels (critical in neonates with kernicterus risk). The liver takes up unconjugated bilirubin via OATP transporters; UGT1A1 enzyme (encoded by the UGT1A1 gene) conjugates it to form bilirubin diglucuronide. Conjugated bilirubin is excreted into bile via MRP2 (ABCC2) transporters and passes into the small intestine. Intestinal bacteria reduce it to urobilinogen; most is excreted in stool (stercobilin — brown color), a small fraction reabsorbed and excreted in urine (StatPearls).

Neonatal physiology: Neonates have a higher RBC turnover rate (fetal hemoglobin transition), immature hepatic UGT1A1 activity, and enhanced enterohepatic recirculation (sterile gut, beta-glucuronidase activity). These factors combine to produce physiologic hyperbilirubinemia in 60% of term and 80% of preterm infants. Phototherapy converts unconjugated bilirubin to water-soluble photoisomers (lumirubin, Z-lumirubin) that can be excreted without conjugation (AAP 2004 Guideline; updated by AAP 2022 guidelines per Kemper et al., Pediatrics 2022).

Obstructive pathophysiology: Biliary obstruction (gallstones, strictures, malignancy) impairs excretion of conjugated bilirubin into the intestine. Conjugated bilirubin backs up into the bloodstream (conjugated hyperbilirubinemia), spills into urine (bilirubinuria/dark urine), and prevents stercobilin formation (pale stools). Cholestasis also triggers bile acid accumulation — responsible for severe pruritus and hepatocellular damage if prolonged.

Hepatocellular pathophysiology: In hepatocellular disease (hepatitis, cirrhosis, DILI), both unconjugated and conjugated bilirubin may accumulate due to impaired uptake, conjugation, and excretion. The pattern is typically mixed hyperbilirubinemia. Portal hypertension, coagulopathy (impaired clotting factor synthesis), hypoalbuminemia, and encephalopathy may accompany severe hepatocellular jaundice.

Kernicterus mechanism: When unconjugated bilirubin exceeds albumin-binding capacity (high bilirubin levels, low albumin, acidosis, or displacing drugs), free bilirubin crosses the BBB and deposits in the basal ganglia (globus pallidus, subthalamic nucleus), cerebellum, and hippocampus, causing oxidative damage and neuronal death. Sequelae include athetoid cerebral palsy, auditory neuropathy, gaze abnormalities, and cognitive impairment (StatPearls — Kernicterus).

💊 Medication Impact / Treatment

Phototherapy (neonatal): First-line treatment for neonatal hyperbilirubinemia. Conventional phototherapy uses blue-green light (460–490 nm wavelength) to convert unconjugated bilirubin to water-soluble photoisomers. Intensive/double phototherapy is used for high-risk neonates or rapidly rising bilirubin. The 2022 AAP guidelines provide updated risk-stratified Bhutani nomogram thresholds for initiating and escalating phototherapy based on gestational age, postnatal age (hours), and neurotoxicity risk factors (Kemper et al., Pediatrics 2022). Home phototherapy (HCPCS E0202) may be used in selected low-risk infants. Phototherapy CPT 94780 was removed from CPT; billing is via appropriate E/M codes plus facility charges.

Exchange transfusion: Reserved for severe/refractory hyperbilirubinemia or acute bilirubin encephalopathy. Double-volume exchange transfusion removes bilirubin and sensitized RBCs and provides albumin. Used in HDN (P55.x) with kernicterus risk.

Intravenous immunoglobulin (IVIG): Used adjunctively in HDN (ABO/Rh isoimmunization) to reduce hemolysis and avoid exchange transfusion. Document IVIG use and indication clearly for coding and coverage purposes.

Ursodeoxycholic acid (UDCA / Ursodiol): Treatment for intrahepatic cholestasis of pregnancy (O26.6x) and primary biliary cholangitis. Reduces bile acid toxicity and pruritus. May be used in inspissated bile syndrome neonatally.

Cholestyramine: Bile acid sequestrant; used for cholestatic pruritus management in adults (PSC, PBC, ICP).

Drugs that may precipitate or worsen jaundice (DILI — K71.x): Isoniazid, rifampin, amoxicillin-clavulanate, statins, acetaminophen (toxic hepatitis at high doses), anabolic steroids, oral contraceptives, antifungals (azoles), methotrexate. Document specific offending agent when drug-induced liver injury (K71.x) is diagnosed.

Drugs that displace bilirubin from albumin (neonatal risk): Sulfonamides, ceftriaxone (avoid in neonates with hyperbilirubinemia), ibuprofen; these increase free bilirubin and kernicterus risk. Document any such drug use in the neonatal record.

Tin-mesoporphyrin (SnMP): Investigational heme oxygenase inhibitor to reduce bilirubin production; not yet FDA approved for clinical use in neonates.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines from the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (CMS) apply to jaundice coding:

Neonatal Jaundice (Chapter 16 — Perinatal)

• Guideline I.C.16.a: Perinatal codes (P00–P96) are used for newborns from birth through the 28th day after delivery. They take priority over codes from other chapters when coding conditions originating in the perinatal period, even if the condition continues beyond 28 days.
• Code specificity: Always code the most specific neonatal jaundice code available. P59.0–P59.9 subcategories reflect etiology. If the cause is documented (e.g., HDN, hepatocellular damage, breast-milk), assign the specific code rather than P59.9 (unspecified).
• P55.x and P57.x: Hemolytic disease due to isoimmunization (P55.x) may be coded alongside jaundice codes (P59.x) when both conditions are documented. Kernicterus (P57.x) is a complication — assign as an additional code when documented by the provider, in addition to P55.x or P59.x as appropriate.
• Physiologic vs. pathologic: Physiologic jaundice in a well term neonate is often coded P59.9. However, when phototherapy is ordered, the clinical significance exceeds “physiologic” — the provider should document the clinical significance; CDI should query for pathologic vs. physiologic distinction if phototherapy was initiated.

Adult / General Jaundice

• R17 (Unspecified jaundice): R17 is a symptom code from Chapter 18. It should be used only when jaundice is a presenting symptom not explained by a definitive diagnosis. When a specific cause is identified (hepatitis, gallstones, cirrhosis, etc.), assign the etiology code rather than R17.
• Sequencing: When jaundice is the presenting complaint and a specific etiology is established during the encounter, sequence the etiology as principal diagnosis (e.g., K80.51 cholelithiasis with obstruction) and list R17 as an additional code only if specifically documented as a separate problem — or omit if subsumed by the etiology code.
• Cholestasis (K83.1): Cholestasis may be coded as a manifestation of another hepatic condition or as a condition in its own right when documented. It excludes neonatal cholestasis (P59.1).
• Gilbert Syndrome (E80.4) and Crigler-Najjar (E80.5): These are inherited metabolic disorders. Per Tabular instruction, they are coded from Chapter 4 (Endocrine, Nutritional, and Metabolic Diseases). Do not substitute R17 when these diagnoses are documented.
• Pregnancy (O26.6x — Jaundice in pregnancy): Per Chapter 15 guidelines (Obstetric conditions), O codes take precedence when coding jaundice in pregnant patients. Use O26.61–O26.63 (by trimester) for intrahepatic cholestasis of pregnancy. An additional code for the specific liver condition may be assigned.
• Drug-induced liver injury (K71.x): When jaundice is due to a medication, assign the appropriate K71 code plus an adverse effect code (T36–T50 with 5th/6th character A, D, S) to identify the drug. Document drug name, dose, and causality determination (definite, probable, possible) in clinical notes.

🔢 ICD-10-CM Code Set (FY2026)

🔎 Indexing

Key Alphabetic Index entries from the FY2026 ICD-10-CM Tabular List and Index (NCHS/CDC):

• Jaundice → R17
  • Jaundice, neonatal → see Jaundice, newborn
  • Jaundice, newborn P59.9
    • due to or associated with — breast milk P59.3; hepatocellular damage P59.20; isoimmunization P55.9; preterm delivery P59.0
  • Jaundice, obstructive → K83.1 (see also Obstruction, bile duct)
  • Jaundice, hemolytic → D59.9 (acquired) or see specific hemolytic anemia
• Icterus → see Jaundice
• Kernicterus (of newborn) → P57.9; due to isoimmunization → P57.0
• Hemolytic disease of newborn → P55.9; due to Rh → P55.0; due to ABO → P55.1
• Inspissated bile syndrome (newborn) → P59.1
• Cholestasis → K83.1; neonatal → P59.1; of pregnancy → O26.6x
• Gilbert disease/syndrome → E80.4
• Crigler-Najjar disease/syndrome → E80.5
• Hyperbilirubinemia, neonatal → P59.9 (or specific subcategory)
• Anemia, G6PD deficiency → D55.0
• Hepatitis, toxic → K71.x (with 5th character for type)
• Obstruction, bile duct → K83.1; with calculus → K80.51

🏥 CPT (2026)

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following represent key guidance topics from AHA Coding Clinic relevant to jaundice coding. CDI and coding professionals should consult the applicable Coding Clinic issues directly for complete guidance:

• Neonatal jaundice etiology specificity: AHA Coding Clinic has consistently reinforced that coders should assign the most specific neonatal jaundice subcategory when clinical documentation supports it, rather than defaulting to P59.9. When the provider documents a specific cause (e.g., G6PD deficiency, ABO incompatibility, breast milk), the appropriate specific code should be assigned.
• Breast-milk jaundice vs. breastfeeding jaundice: Coding Clinic guidance clarifies the distinction between P59.3 (breast-milk jaundice — from inhibitors in breast milk) and the coding of early-onset jaundice associated with breastfeeding difficulties — the latter coded as feeding problem plus P59.9 rather than P59.3.
• Kernicterus documentation: Coding Clinic has emphasized that P57.x (kernicterus) should only be assigned when explicitly documented by the treating provider. Coders should not infer kernicterus from bilirubin levels alone; a CDI query is appropriate when neurologic signs of bilirubin encephalopathy are documented but kernicterus is not explicitly named.
• R17 vs. specific etiology: Repeated Coding Clinic guidance reinforces that R17 is a symptom code of last resort. When the clinical record documents the cause of jaundice (biliary obstruction, hepatitis, hemolytic anemia), the etiology code should be assigned instead of or in addition to R17.
• Drug-induced cholestatic jaundice (K71.0): Coding Clinic guidance on DILI instructs coders to assign K71.x with the appropriate adverse effect code (T-code), documenting drug name and intent (therapeutic use, overdose, etc.). The jaundice (R17) may be listed additionally if separately documented as a clinical finding.
• Intrahepatic cholestasis of pregnancy: Guidance affirms that O26.6x is the appropriate code for ICP in pregnant patients, with the trimester specified. Additional codes for jaundice (R17) or specific liver findings may be assigned as needed per the OB provider’s documentation.

💰 HCC / Risk Adjustment (v28)

Under the CMS-HCC Model Version 28 (effective 2024–2026), jaundice-related codes map as follows:

✍️ CDI Query Templates

All query templates below follow ACDIS and AHIMA compliant non-leading, multiple-choice format. Queries should be placed in the medical record per facility policy, signed by a CDI specialist, and responded to by the treating provider.

🧑‍⚕️ Treatments (Clinical)

Neonatal Hyperbilirubinemia:

• Phototherapy — Standard of care for elevated neonatal bilirubin per AAP Bhutani nomogram thresholds. Blue-spectrum fluorescent lamps or LED devices deliver 460–490 nm light. Single-surface vs. double/intensive phototherapy (all skin surface exposure) for high-risk neonates. Efficacy monitored by bilirubin rechecks every 4–12 hours. Home phototherapy (biliblanket, HCPCS E0202) used for lower-risk infants with close outpatient follow-up per AAP 2022 guidance (Kemper et al., Pediatrics 2022).
• Exchange transfusion — Double-volume exchange transfusion (160–200 mL/kg) for severe hyperbilirubinemia at exchange threshold per Bhutani nomogram, or for acute bilirubin encephalopathy/kernicterus. Removes bilirubin, maternal antibodies, and sensitized RBCs. Associated with significant procedural risk (mortality ~0.3–0.5% per procedure); benefit-risk assessment critical.
• IVIG — For ABO or Rh HDN (P55.x) — reduces hemolysis and need for exchange transfusion. Dose: 0.5–1 g/kg IV over 2–4 hours; may repeat once (AAP guideline).
• Hydration and feeding support — Adequate feeding (breastfeeding support, supplement if indicated) reduces enterohepatic recirculation. IV hydration for severe cases. Formula supplementation or donor milk may be considered in extreme cases to rapidly reduce bilirubin.

Adult Obstructive Jaundice:

• ERCP with sphincterotomy and stone extraction (CPT 43262, 43264) — First-line for choledocholithiasis (K80.51) causing obstructive jaundice. Endoscopic stone removal relieves biliary obstruction; antibiotics for concurrent cholangitis.
• Laparoscopic cholecystectomy — Definitive treatment for cholelithiasis; performed after biliary decompression in cholangitis.
• Biliary stenting — Endoscopic or percutaneous biliary stent placement for malignant or benign strictures causing obstructive jaundice (e.g., pancreatic cancer, cholangiocarcinoma, PSC).
• Percutaneous transhepatic cholangiography (PTC) — Alternative biliary drainage for cases not amenable to ERCP.

Hepatocellular Jaundice:

• Treat underlying cause — Antivirals (direct-acting antivirals for hepatitis C, tenofovir/entecavir for hepatitis B), corticosteroids for autoimmune hepatitis, cessation of offending drug (DILI), abstinence from alcohol (alcoholic hepatitis).
• Liver transplantation — For end-stage liver disease with refractory jaundice (Model for End-Stage Liver Disease [MELD] score guiding listing priority).
• Supportive care — Lactulose/rifaximin for hepatic encephalopathy; albumin infusion; coagulopathy management (FFP, vitamin K); paracentesis for ascites; sodium restriction.

Gilbert Syndrome / Crigler-Najjar:

• Gilbert syndrome (E80.4): No treatment required; patient education; avoid prolonged fasting, dehydration, stress triggers; reassurance.
• Crigler-Najjar Type I (E80.5): Lifelong 12–16 hours/day phototherapy until liver transplantation; liver transplant is curative and should be performed before irreversible kernicterus.
• Crigler-Najjar Type II (E80.5): Often managed with phenobarbital (induces residual UGT1A1); phototherapy may be needed.

🎓 Patient Education / Summary

What is Jaundice?
Jaundice is a yellow coloring of the skin and the whites of the eyes. It happens when a substance called bilirubin builds up in the blood. Bilirubin is a yellow pigment that comes from the natural breakdown of old red blood cells. The liver normally processes and removes it from the body. When the liver is overwhelmed, damaged, or the drainage system is blocked, bilirubin accumulates and causes yellowing.

Jaundice in Newborns:
Newborn jaundice is very common — it affects about 6 in 10 babies. In most cases, it is mild and goes away on its own in 1–2 weeks. However, in some newborns — especially premature babies or babies with blood type problems (like Rh or ABO incompatibility) — bilirubin can rise to dangerous levels. Very high bilirubin can damage the brain (a serious condition called kernicterus). Parents should watch for:

• Yellow skin that is spreading from the face down to the belly and legs
• Very sleepy or hard-to-wake baby
• Poor feeding or not enough wet diapers
• High-pitched crying

If your baby has any of these signs, call your pediatrician or go to the emergency room immediately. Newborn jaundice is treated with special blue lights (phototherapy) that help break down bilirubin. Most babies do well with treatment.

Breastfeeding and Jaundice:
Breastfed babies may develop jaundice more often, especially in the first week if they are not getting enough milk. Feeding your baby 8–12 times per day and watching for good weight gain helps prevent this. A second type, called breast-milk jaundice, can appear after the first week and is usually mild. It is caused by something in breast milk that affects how bilirubin is processed. Most mothers can continue breastfeeding — talk to your baby’s doctor or a lactation consultant for guidance.

Jaundice in Adults:
In adults, jaundice is always a sign that the liver, gallbladder, or bile ducts need attention. Common causes include gallstones blocking the bile duct, liver inflammation (hepatitis), liver scarring (cirrhosis), or certain medications. See a doctor promptly if you notice yellow skin or eyes, dark (tea-colored) urine, or pale stools. Early evaluation helps identify the cause and start appropriate treatment.

For More Information:

• NIDDK — Jaundice in Newborns and Adults
• American Academy of Pediatrics — Newborn Jaundice
• ACOG — Obstetric Cholestasis (ICP)

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)